Subscribe

Drugs Frequently Used in the Treatment of Cancer and Their Associated Codes and Pricing

The following tables of frequently used oncology drugs are intended to assist practice managers, other healthcare providers, and payers in the proper use of coding and billing information associated with the treatment of their patients. For the latest and most detailed pricing (including all package sizes), please go to BuyandBill.com or PriceDoctoRx.com.

Please click on an oncology drug's brand name to view additional information on BuyandBill.com.
  1. Table 1
  2. Table 2

  1. TABLE 1Office-Administered Oncology Drugs and Corresponding Codes and Pricing

    ASP+6% per unit, lowest WAC per unit, and lowest AWP per unit values are up to date as of 10/1/2021.

    1. A-B
    2. C-F
    3. G-I
    4. J-M
    5. N-Q
    6. R-Z
    1. paclitaxel albumin-stabilized nanoparticle formulation
      Celgene Corporation
      J9264
      $14.08
      $15.12
      $18.14
      1/1/2021
      tocilizumab
      Genentech
      J3262
      $5.55
      $5.76
      $6.92
      1/1/2020
      brentuximab vedotin
      Seattle Genetics
      J9042
      $189.34
      $185.50
      $222.60
      6/30/2021
      netupitant and palonosetron hydrochloride
      Helsinn Therapeutics (US)
      J1454
      $571.22
      $683.18
      $819.82
      7/1/2021
      pemetrexed disodium
      Eli Lilly and Company
      J9305
      $74.93
      $76.97
      $92.36
      7/1/2021
      copanlisib hydrochloride
      Bayer
      J9057
      N/A
      $79.30
      $95.16
      1/1/2021
      darbepoetin alfa
      Amgen USA
      J0881
      $3.15
      $7.74
      $9.29
      1/17/2017
      ofatumumab
      Novartis Pharmaceuticals Corporation
      J9302
      $63.96
      $60.34
      $72.40
      1/3/2020
      bevacizumab
      Genentech
      J9035
      $70.41
      $79.69
      $95.63
      6/3/2019
      avelumab
      EMD Serono
      J9023
      $86.19
      $85.13
      $102.16
      7/1/2021
      bendamustine hydrochloride
      Teva
      J9034
      $19.65
      $24.74
      $29.69
      3/23/2018
      inotuzumab ozogamicin
      Pfizer (Wyeth)
      J9229
      $2,371.62
      $2,270.94
      $2,725.11
      7/1/2021
      belantamab mafodotin-blmf
      GlaxoSmithKline
      J9037
      $42.78
      $42.01
      $50.41
      7/1/2021
      blinatumomab
      Amgen USA
      J9039
      $123.88
      $121.20
      $145.44
      1/22/2021
      lisocabtagene maraleucel
      Bristol-Myers Squibb Company
      Q2054
      $422,609.00b
      $410,300.00
      $492,360.00
      2/5/2021
    2. irinotecan hydrochloride
      Multi-source, generica
      J9206
      $2.35
      $3.60
      $4.32
      5/6/2019
      trilaciclib
      G1 Therapuetics
      J1448
      $4.97
      $4.72
      $5.67
      2/22/2021
      ramucirumab
      Eli Lilly and Company
      J9308
      $62.69
      $62.81
      $75.38
      7/1/2021
      daratumumab
      Janssen Biotech
      J9145
      $57.55
      $58.24
      $69.88
      1/15/2021
      daratumumab and hyaluronidase-fihj
      Janssen Biotech
      J9144
      $45.10
      $44.10
      $52.92
      1/15/2021
      rasburicase
      Sanofi-Aventis
      J2783
      $315.06
      $319.34
      $383.21
      7/1/2021
      epirubicin hydrochloride
      Multi-source, generica
      J9178
      $1.69
      $1.85
      $2.22
      1/1/2021
      elotuzumab
      Bristol-Myers Squibb Company
      J9176
      $6.77
      $6.67
      $8.00
      7/1/2021
      fam-trastuzumab deruxtecan-nxki
      Daiichi Sankyo
      J9358
      $24.27
      $23.65
      $28.38
      7/1/2021
      epoetin alfa
      Amgen USA
      J0885
      $8.15
      $16.58
      $19.90
      1/17/2017
      cetuximab
      Eli Lilly and Company
      J9055
      $66.71
      $69.34
      $83.21
      7/1/2021
      asparaginase Erwinia chrysanthemi
      Jazz Pharmaceuticals
      J9019
      $427.27
      $403.08
      $483.70
      6/28/2021
      fulvestrant
      AstraZeneca
      J9395
      $15.98
      $96.95
      $116.34
      1/1/2019
      pegfilgrastim
      Mylan Institutional LLC
      Q5108
      $211.19
      $347.92
      $417.50
      7/9/2018
    3. obinutuzumab
      Genentech
      J9301
      $64.54
      $68.49
      $82.19
      1/1/2021
      gemcitabine hydrochloride
      Multi-source, generica
      J9201
      $3.82
      $7.70
      $9.24
      2/19/2019
      filgrastim
      Teva (Cephalon)
      J1447
      $0.46
      $0.83
      $1.00
      9/4/2018
      eribulin mesylate
      Genentech
      J9355
      $89.81
      $103.89
      $124.67
      6/3/2019
      trastuzumab and hyaluronidase-oysk
      Genentech
      J9356
      $71.85
      $77.92
      $93.50
      4/8/2019
      topotecan hydrochloride
      Multi-source, generica
      J9351
      $0.77
      $2.67
      $3.21
      5/14/2013
      idarubicin hydrochloride
      Multi-source, generica
      J9211
      $34.75
      $30.00
      $36.00
      4/26/2018
      durvalumab
      AstraZeneca
      J9173
      $76.86
      $74.40
      $89.28
      7/1/2020
      talimogene laherparepvec
      Amgen USA
      J9325
      $57.26
      $54.86
      $65.83
      1/22/2021
      gemcitabine hydrochloride
      Sun Pharmaceutical Industries
      J9198
      $34.00
      $38.00
      $45.60
      4/8/2019
      recombinant interferon alfa-2b
      Merck Sharp & Dohme Corp
      J9214
      $33.24
      $30.73
      $36.88
      1/5/2018
      romidepsin
      Multi-source, generica
      J9315
      N/A
      $319.87
      $383.84
      10/6/2017
    4. cabazitaxel
      Sanofi-Aventis
      J9043
      $189.00
      $202.09
      $242.51
      7/1/2021
      ado-trastuzumab emtansine
      Genentech
      J9354
      $34.18
      $32.96
      $39.56
      1/1/2021
      pembrolizumab
      Merck Sharp & Dohme Corp.
      J9271
      $52.75
      $51.34
      $61.61
      9/30/2021
      tisagenlecleucel
      Novartis Pharmaceuticals Corporation
      Q2042
      $434,337.60b
      $373,000.00
      $447,600.00
      5/1/2018
      carfilzomib
      Amgen USA
      J9047
      $41.10
      $42.99
      $51.58
      1/22/2021
      cemiplimab-rwlc
      Regeneron Pharmaceuticals
      J9119
      $27.54
      $26.92
      $32.30
      8/6/2021
      moxetumomab pasudotox-tdfk
      AstraZeneca (Innate Pharma)
      J9313
      $23.39
      $22.07
      $26.48
      10/1/2020
      tafasitamab-cxix
      Morphosys US
      J9349
      $12.62
      $12.18
      $14.62
      7/1/2021
      bevacizumab
      Amgen USA
      Q5107
      $44.56
      $69.77
      $83.73
      8/18/2021
      gemtuzumab ozogamicin
      Pfizer (Wyeth)
      J9203
      $207.99
      $199.16
      $239.00
      7/1/2021
    5. paclitaxel albumin-stabilized nanoparticle formulation
      Multi-source, generica
      J9267
      $0.13
      $0.11
      $0.19
      8/7/2014
      pegfilgrastim
      Amgen USA
      J2505
      $2,221.63
      $6,417.99
      $7,701.56
      8/8/2021
      filgrastim
      Amgen USA
      J1442
      $0.97
      $1.04
      $1.25
      10/19/2017
      romiplostim
      Amgen USA
      J2796
      $83.47
      $82.59
      $99.10
      1/22/2021
      pegfilgrastim
      Pfizer
      Q5122
      $284.69
      $130.83
      $157.00
      11/30/2020
      irinotecan hydrochloride liposome
      Ipsen Biopharmaceuticals
      J9205
      $57.20
      $57.49
      $68.99
      1/12/2021
      nivolumab
      Bristol-Myers Squibb Company
      J9299
      $28.86
      $28.25
      $33.90
      8/31/2021
      enfortumab vedotin-ejfv
      Seattle Genetics
      J9177
      $30.17
      $29.56
      $35.48
      9/30/2021
      pertuzumab
      Genentech
      J9306
      $13.56
      $13.17
      $15.80
      1/1/2021
      pertuzumab, trastuzumab, and hyaluronidase-zzxf
      Genentech
      J9316
      $72.15
      $70.59
      $84.71
      7/6/2020
      polatuzumab vedotin-piiq
      Genentech
      J9309
      $113.57
      $107.14
      $128.57
      9/28/2020
      necitumumab
      Eli Lilly and Company
      J9295
      $5.74
      $5.41
      $6.49
      12/28/2018
      epoetin alfa
      Janssen Products
      J0885
      $8.15
      $26.73
      $32.07
      1/10/2019
      denosumab
      Amgen USA
      J0897
      $21.19
      $22.57
      $27.80
      1/22/2021
    6. epoetin alfa
      Pfizer
      Q5105
      $0.87
      $1.10
      $1.32
      11/9/2020
      rituximab
      Genentech
      J9312
      $86.94
      $93.95
      $112.74
      6/3/2019
      rituximab and hyaluronidase human
      Genentech
      J9311
      $37.94
      $46.98
      $56.37
      7/1/2018
      docetaxel
      Multi-source, generica
      J9171
      $0.48
      $1.06
      $1.27
      2/14/2018
      atezolizumab
      Genentech
      J9022
      $79.75
      $78.92
      $94.70
      1/1/2021
      bendamustine hydrochloride
      Teva
      J9033
      $22.01
      $29.72
      $35.66
      1/1/2018
      rituximab
      Teva (Cephalon)
      Q5115
      $60.58
      $84.55
      $101.47
      11/9/2019
      pegfilgrastim
      Coherus Biosciences
      Q5111
      $222.38
      $347.92
      $417.50
      1/3/2019
      bortezomib
      Millennium Pharmaceuticals
      J9041
      $45.16
      $45.80
      $54.96
      7/1/2016
      azacitidine
      Celgene
      J9025
      $0.93
      $1.00
      $1.20
      9/8/2020
      denosumab
      Amgen USA
      J0897
      $21.19
      $20.76
      $24.91
      1/22/2021
      pegfilgrastim
      Sandoz
      Q5120
      $245.43
      $327.13
      $392.55
      11/7/2019
      bevacizumab-bvzr
      Pfizer
      Q5118
      $52.37
      $61.34
      $73.61
      12/31/2019
      zoledronic acid
      Novartis Pharmaceuticals Corporation
      J3489
      $8.25
      $11.00
      $13.20
      10/12/2020
    aProviders should check with their vendors for the lowest available pricing on multi-source products.
    bAPC rate.
    APC indicates ambulatory payment classification; ASP, average sales price; AWP, average wholesale price; HCPCS, Healthcare Common Procedure Coding System; N/A, not available; WAC, wholesale acquisition cost.

  2. TABLE 2Self-Administered Oncology Drugs and Corresponding Pricing

    1. A-B
    2. C-F
    3. G-I
    4. J-M
    5. N-Q
    6. R-Z
    1. everolimus
      Novartis Pharmaceuticals Corporation
      $536.30
      $643.56
      1/15/2019
      alectinib
      Genentech
      $66.07
      $79.29
      1/1/2021
      brigatinib
      Takeda
      $189.17
      $227.00
      1/4/2021
      exemestane
      Pfizer (Pharmacia and Upjohn)
      $36.90
      $44.28
      1/1/2021
      avapritinib
      Blueprint Medicines
      $1,118.93
      $1,342.72
      6/16/2021
      erdafitinib
      Janssen
      $295.69
      $354.83
      1/15/2021
      bosutinib
      Pfizer
      $137.14
      $164.57
      1/1/2021
      encorafenib
      Array Biopharma
      $70.43
      $84.51
      1/1/2021
      zanubrutinib
      BeiGene USA
      $112.43
      $134.91
      2/1/2021
    2. cabozantinib-s-malate
      Exelixis
      $722.09
      $866.51
      1/1/2021
      acalabrutinib
      AstraZeneca
      $234.40
      $281.28
      10/31/2017
      cabozantinib-s-malate
      Exelixis
      $160.71
      $192.85
      1/1/2020
      duvelisib
      Secura Bio
      $267.23
      $320.67
      4/26/2021
      cobimetinib fumarate
      Genentech
      $111.19
      $133.43
      1/1/2018
      glasdegib maleate
      Pfizer
      $311.00
      $373.20
      1/1/2021
      aprepitant
      Merck Sharp & Dohme Corp.
      $218.77
      $262.53
      1/5/2018
      vismodegib
      Genentech
      $420.20
      $504.25
      1/1/2021
      apalutamide
      Janssen
      $106.94
      $128.33
      1/15/2021
    3. afatinib dimaleate
      Boehringer
      $336.08
      $403.30
      1/1/2021
      imatinib mesylate
      Novartis
      $93.64
      $112.37
      7/7/2015
      palbociclib
      Pfizer
      $622.47
      $746.96
      1/1/2021
      ponatinib hydrochloride
      Ariad Pharma
      $552.03
      $662.44
      10/1/2016
      enasidenib mesylate
      Celgene
      $941.53
      $1,129.84
      1/1/2021
      ibrutinib
      Pharmacyclics
      $165.78
      $198.94
      1/1/2021
      axitinib
      Pfizer
      $92.38
      $110.86
      1/1/2021
      decitabine and cedazuridine
      Taiho
      $1,499.00
      $1,798.80
      8/17/2020
      fedratinib hydrochloride
      Celgene
      $182.88
      $219.45
      1/1/2021
      gefitinib
      AstraZeneca
      $259.63
      $311.55
      4/1/2019
    4. ruxolitinib phosphate
      Incyte Corporation
      $252.05
      $302.46
      10/7/2021
      ribociclib
      Novartis
      $224.93
      $269.91
      1/6/2021
      lenvatinib mesylate
      Eisai
      $226.25
      $271.51
      7/13/2021
      trifluridine and tipiracil hydrochloride
      Taiho Oncology
      $179.22
      $215.07
      1/12/2021
      lorlatinib
      Pfizer
      $196.68
      $236.02
      1/1/2021
      sotorasib
      Amgen
      $74.58
      $89.50
      5/28/2021
      olaparib
      AstraZeneca
      $120.41
      $144.49
      7/1/2020
      trametinib dimethyl sulfoxide
      Novartis
      $123.41
      $148.09
      1/6/2021
      binimetinib
      Array Biopharma
      $69.10
      $82.91
      1/1/2021
    5. neratinib maleate
      Puma Biotech
      $102.07
      $122.48
      8/1/2021
      sorafenib tosylate
      Bayer
      $173.00
      $207.60
      1/1/2021
      ixazomib citrate
      Takeda
      $3,631.33
      $4,357.60
      1/4/2021
      darolutamide
      Bayer
      $99.14
      $118.97
      1/1/2021
      sonidegib
      Sun Pharma
      $415.40
      $498.48
      4/1/2021
      azacitidine
      Celgene
      $1,511.29
      $1,813.55
      3/8/2021
      pemigatinib
      Incyte Corporation
      $1,214.29
      $1,457.14
      4/20/2020
      alpelisib
      Novartis
      $624.90
      $749.88
      1/6/2021
      alpelisib
      Novartis
      $312.45
      $374.94
      1/6/2021
      pomalidomide
      Celgene
      $907.61
      $1,089.13
      1/1/2021
      eltrombopag olamine
      Novartis
      $188.01
      $225.61
      1/6/2021
    6. lenalidomide
      Celgene
      $797.34
      $956.81
      1/1/2021
      entrectinib
      Genentech
      $192.27
      $230.72
      1/1/2021
      rucaparib camsylate
      Clovis Oncology
      $144.75
      $173.70
      4/1/2021
      dasatinib
      Bristol-Myers Squibb Company
      $140.20
      $168.24
      1/1/2021
      sunitinib malate
      Pfizer
      $202.09
      $242.51
      1/1/2021
      abemaciclib
      Lilly
      $233.18
      $279.81
      1/12/2021
      crizotinib
      Pfizer
      $309.78
      $371.73
      1/1/2021
      capecitabine
      Genentech
      $13.56
      $16.27
      1/1/2017
      selinexor
      Karyopharm Therapeutics
      $721.19
      $865.43
      4/1/2021
      vorinostat
      Merck Sharp & Dohme Corp.
      $125.08
      $150.10
      1/5/2018
    AWP indicates average wholesale price; NDC, National Drug Code; WAC, wholesale acquisition cost.
Return to Top of Table

This information was supplied by:

Buy and Bill & Price DoctoRX
CONNECT
Subscribe

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to receive the free OPM print publications or weekly e‑Newsletter.

I'd like to receive:

Sign Up for Oncology News

Subscribe to recieve the free, monthly OPM print publication and OPM weekly e‑newsletter.

Subscribe
©. Engage Healthcare Communications, LLC. All Rights Reserved. Privacy Policy.